AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23817279 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional expression influenced by gender (RR = 1.85), age (RR = 1.03), and education (RR = 0.54)
Number of subjects: 30
Study 23817279 — intervention group
Group type: EXPERIMENTAL
Intervention: Three trajectory groups for positive emotional expression: low stable, fluctuating afternoon peaking, and fluctuating morning peaking
Number of subjects: 30
Study 23817279 — intervention group
Group type: EXPERIMENTAL
Intervention: Two trajectory groups for negative emotional expression: consistent pattern and inconsistent pattern
Number of subjects: 30
Study 20497439 — intervention group
Group type: COMPARATOR
Intervention: Flapless group
Number of subjects: 52
Study 20497439 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 20497439 — intervention group
Group type: COMPARATOR
Intervention: BSG group
Number of subjects: 52
Study 18769863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and famciclovir (P+F group)
Number of subjects: 167
Study 18769863 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (P group)
Number of subjects: 167
Study 16637747 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) measuring automatic fear associations in spider fearful participants
Number of subjects: 0
Study 16637747 — intervention group
Group type: COMPARATOR
Intervention: Implicit Association Test (IAT) measuring automatic fear associations in nonfearfuls and spider enthusiasts
Number of subjects: 0
Study 12643608 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 0
Study 12643608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 0
Study 12643608 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori negative with no mucosal lesions)
Number of subjects: 0
Study 12643608 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori negative with lesions)
Number of subjects: 0
Study 12643608 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori positive with lesions)
Number of subjects: 0
Study 12643608 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori negative)
Number of subjects: 0
Study 12643608 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (in vitro biopsy incubation)
Number of subjects: 0
Study 10827333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (OC) containing ethinyl estradiol 20 microg and 0.1 mg levonorgestrel
Number of subjects: 30
Study 10827333 — intervention group
Group type: COMPARATOR
Intervention: Lunelle (injectable contraceptive containing estradiol cypionate 5 mg and medroxyprogesterone acetate 25 mg)
Number of subjects: 30
Study 10827333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive (OC)
Number of subjects: 30
Study 10827333 — intervention group
Group type: COMPARATOR
Intervention: Lunelle
Number of subjects: 30
Study 8863203 — intervention group
Group type: EXPERIMENTAL
Intervention: Benomyl (Benlate 50 DF) exposure
Number of subjects: 0
Study 8863203 — intervention group
Group type: COMPARATOR
Intervention: No exposure to benomyl (control group)
Number of subjects: 0
Study 1487095 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-band compressor (condition C)
Number of subjects: 20
Study 1487095 — intervention group
Group type: COMPARATOR
Intervention: Linear amplifier (condition L)
Number of subjects: 20
Study 1487095 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids normally worn (condition Own)
Number of subjects: 20
Study 1487095 — intervention group
Group type: COMPARATOR
Intervention: Without hearing aids (condition U)
Number of subjects: 20
Study 2982563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid gel (6 X 12 ml/d; neutralisation capacity 120 mmol)
Number of subjects: 125
Study 2982563 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g/d)
Number of subjects: 125
Study 30560740 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for 6 weeks
Number of subjects: 42
Study 30560740 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 42
Study 30400138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked B. carinata
Number of subjects: 22
Study 30400138 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw B. carinata
Number of subjects: 22
Study 27209068 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered progressive resistance exercise performed twice a week for 15 weeks
Number of subjects: 67
Study 25493671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine antimicrobial dressing
Number of subjects: 85
Study 25493671 — intervention group
Group type: COMPARATOR
Intervention: Gauze and micro porous tape
Number of subjects: 85
Study 22908836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 atm abs (breathing 100% oxygen)
Number of subjects: 42
Study 22908836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 atm abs (breathing air)
Number of subjects: 42
Study 22908836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure changes (1.2 atm abs and 1.5 atm abs)
Number of subjects: 42
Study 20234324 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoaxial screw insertion
Number of subjects: 66
Study 20234324 — intervention group
Group type: COMPARATOR
Intervention: Polyaxial screw insertion
Number of subjects: 66
Study 20234324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 66
Study 20234324 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-shaft angle < 130 degrees
Number of subjects: 66
Study 20234324 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-shaft angle > 130 degrees
Number of subjects: 66
Study 18074484 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 2580
Study 18074484 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifiers (HHs)
Number of subjects: 2580
Study 15752388 — intervention group
Group type: EXPERIMENTAL
Intervention: cAAI-guided propofol infusion (Group G, n = 10)
Number of subjects: 20
Study 15752388 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical practice (Group C, n = 10)
Number of subjects: 20
Study 15752388 — intervention group
Group type: EXPERIMENTAL
Intervention: cAAI values in Group G
Number of subjects: 20
Study 15752388 — intervention group
Group type: COMPARATOR
Intervention: cAAI values in Group C
Number of subjects: 20
Study 12027841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane titration with A‐line auditory guidance (target auditory evoked potential index of 30+/‐5)
Number of subjects: 60
Study 12027841 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane titration clinically (without AEP guidance)
Number of subjects: 60
Study 10439477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum preparation standardised to 0.17 mg total hypericin per day (114 patients)
Number of subjects: 348
Study 10439477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum preparation standardised to 0.33 mg total hypericin per day (115 patients)
Number of subjects: 348
Study 10439477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum preparation standardised to 1 mg total hypericin per day (119 patients)
Number of subjects: 348
Study 10439477 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 348
Study 7852667 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (0.56 mg/day)
Number of subjects: 35
Study 7852667 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms/day)
Number of subjects: 35
Study 7852667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2181434 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (exact dosage not specified)
Number of subjects: 140
Study 2181434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (exact dosage not specified)
Number of subjects: 140
Study 322794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10
Study 322794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 322794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (doubled dose)
Number of subjects: 10
Study 31201191 — intervention group
Group type: EXPERIMENTAL
Intervention: STHLM3 test and MRI-targeted biopsies
Number of subjects: 10000
Study 31201191 — intervention group
Group type: COMPARATOR
Intervention: Prostate-specific antigen (PSA) and systematic biopsies
Number of subjects: 10000
Study 27693443 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 15
Study 27693443 — intervention group
Group type: COMPARATOR
Intervention: Normal exercise clothes (Control)
Number of subjects: 15
Study 25896891 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT septal pacing
Number of subjects: 80
Study 25896891 — intervention group
Group type: COMPARATOR
Intervention: RVAP
Number of subjects: 80
Study 23871349 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural anticoagulation
Number of subjects: 635
Study 21586127 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical evacuation of the haematoma within 12 hours
Number of subjects: 600
Study 21586127 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative treatment
Number of subjects: 600
Study 21586127 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical evacuation
Number of subjects: 600
Study 19710593 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (200 mg twice daily)
Number of subjects: 1203
Study 16794492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1484
Study 12636120 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxide and light
Number of subjects: 87
Study 12636120 — intervention group
Group type: COMPARATOR
Intervention: Peroxide control (peroxide gel)
Number of subjects: 87
Study 12636120 — intervention group
Group type: COMPARATOR
Intervention: Light control (placebo gel and light)
Number of subjects: 87
Study 10992827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 101
Study 10992827 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (1.2 g)
Number of subjects: 101
Study 10992827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol and Metamizol combined in 1:1 ratio
Number of subjects: 101
Study 10992827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol and Metamizol combined in 1:0.3 ratio
Number of subjects: 101
Study 10992827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol and Metamizol combined in 1:3 ratio
Number of subjects: 101
Study 9109909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 23
Study 9109909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1609380 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 minute protocol with two sudden bursts of three minute high intensity exercise, preceded by three minutes of low level exercise
Number of subjects: 19
Study 1609380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional three minute incremental test lasting 12 minutes
Number of subjects: 19
Study 1609380 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial burst of high intensity exercise
Number of subjects: 19
Study 1609380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 19
Study 3903736 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 3903736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 31808664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed SVV fluid strategy group (n=57)
Number of subjects: 118
Study 31808664 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual SVV group (n=61)
Number of subjects: 118
Study 30395050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 1.49 ± 0.44 g·kg·d for oxidation (Ox)
Number of subjects: 8
Study 30395050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 1.53 ± 0.32 g·kg·d for net protein balance (NB)
Number of subjects: 8
Study 30395050 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake (0.2-2.9 g·kg·d)
Number of subjects: 8
Study 27601060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 3722
Study 27618886 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betuline gel (TBG)
Number of subjects: 220
Study 27618886 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 220
Study 25842575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Disc Arthroplasty
Number of subjects: 42
Study 25842575 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Number of subjects: 42
Study 22234041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing n-3 polyunsaturated fatty acids (2 cans/day, 2.02 g eicosapentaenoic acid + 0.92 g docosahexaenoic acid/day)
Number of subjects: 40
Study 22234041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing n-3 polyunsaturated fatty acids
Number of subjects: 40
Study 22234041 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control supplement
Number of subjects: 40
Study 20194829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CBGT + phenelzine)
Number of subjects: 128
Study 20194829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 128
Study 20194829 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 128
Study 20194829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17322426 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg b/d)
Number of subjects: 250
Study 17322426 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg t.d.s)
Number of subjects: 250
Study 15662518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs
Number of subjects: 0
Study 15662518 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotic drugs
Number of subjects: 0
Study 15662518 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free patients
Number of subjects: 0
Study 15662518 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 11900994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (10-60 mg once-daily doses of a controlled-release formulation)
Number of subjects: 0
Study 11900994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 0
Study 9990816 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 500 mg clarithromycin + 2 x 1000 mg amoxicillin + 40 mg pantoprazole/day for 7 days
Number of subjects: 99
Study 9990816 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 500 mg clarithromycin + 2 x 400 mg ranitidine bismuth citrate/day for 14 days
Number of subjects: 99
Study 7775320 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in hot water (35 degrees C)
Number of subjects: 18
Study 7775320 — intervention group
Group type: COMPARATOR
Intervention: Training in cold water (20 degrees C)
Number of subjects: 18
Study 7775320 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in hot water and cold water
Number of subjects: 18
Study 7775320 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in cold water
Number of subjects: 18
Study 2181859 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g n-3 FAs/d (group 1)
Number of subjects: 25
Study 2181859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 g n-3 FAs/d (group 2)
Number of subjects: 25
Study 2181859 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (group 3, placebo control)
Number of subjects: 25
Study 7000218 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospital admission
Number of subjects: 0
Study 7000218 — intervention group
Group type: COMPARATOR
Intervention: Standard admission
Number of subjects: 0
Study 30073766 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily for 16 weeks
Number of subjects: 22
Study 30073766 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 16 weeks
Number of subjects: 22
Study 27808426 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 20
Study 27808426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 20
Study 27808426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26399310 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOs (High Frequency Oscillations)
Number of subjects: 78
Study 26399310 — intervention group
Group type: COMPARATOR
Intervention: Interictal spikes
Number of subjects: 78
Study 26399310 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOs
Number of subjects: 78
Study 23942938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrumentation (PSI)
Number of subjects: 40
Study 23942938 — intervention group
Group type: COMPARATOR
Intervention: Conventional Instrumentation (Control)
Number of subjects: 40
Study 21543671 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical reconstruction of the lateral collateral ligament and popliteus tendon with tibialis posterior tendon allograft (Group A)
Number of subjects: 46
Study 21543671 — intervention group
Group type: COMPARATOR
Intervention: Modified biceps rerouting tenodesis (Group B)
Number of subjects: 46
Study 19651410 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-retaining TKR design
Number of subjects: 29
Study 18404608 — intervention group
Group type: EXPERIMENTAL
Intervention: High ACE activity group
Number of subjects: 16
Study 18404608 — intervention group
Group type: COMPARATOR
Intervention: Low ACE activity group
Number of subjects: 16
Study 16255753 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chamber ICDs (S-ICDs)
Number of subjects: 717
Study 16255753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs (D-ICDs)
Number of subjects: 717
Study 12143088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 24
Study 12143088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 24
Study 12143088 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 24
Study 10440558 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 0
Study 10440558 — intervention group
Group type: EXPERIMENTAL
Intervention: As-randomized (intention-to-treat) analysis
Number of subjects: 0
Study 10440558 — intervention group
Group type: EXPERIMENTAL
Intervention: As-treated analysis
Number of subjects: 0
Study 10440558 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates based on a nonignorable selection model
Number of subjects: 0
Study 10440558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubin's causal model
Number of subjects: 0
Study 8589023 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and cisplatin (50 mg/m2)
Number of subjects: 20
Study 2101251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.03% triclosan and 0.25% copolymer
Number of subjects: 20
Study 7230259 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control strategies
Number of subjects: 0
Study 7230259 — intervention group
Group type: COMPARATOR
Intervention: Self-control strategies with covert sensitization
Number of subjects: 0
Study 7230259 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control manual and basic package
Number of subjects: 0
Study 7230259 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic package with cue extinction procedures
Number of subjects: 0
Study 7230259 — intervention group
Group type: COMPARATOR
Intervention: Combination of self-control and cue extinction procedures
Number of subjects: 0
Study 29737099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg voriconazole tablets
Number of subjects: 48
Study 25712491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 294
Study 25712491 — intervention group
Group type: EXPERIMENTAL
Intervention: Education pain intervention
Number of subjects: 294
Study 25712491 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 294
Study 24767206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 151
Study 24767206 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 23071122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (R; 10 mg daily)
Number of subjects: 422
Study 23071122 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (T; 80 mg daily)
Number of subjects: 422
Study 23071122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ramipril and Telmisartan (T+R)
Number of subjects: 422
Study 23071122 — intervention group
Group type: COMPARATOR
Intervention: Clinic BP
Number of subjects: 422
Study 20152972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous support during labor
Number of subjects: 100
Study 20152972 — intervention group
Group type: COMPARATOR
Intervention: Control (no continuous support)
Number of subjects: 100
Study 18823194 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory pip
Number of subjects: 0
Study 18823194 — intervention group
Group type: COMPARATOR
Intervention: Visual cues
Number of subjects: 0
Study 16896736 — intervention group
Group type: EXPERIMENTAL
Intervention: VC (muscular contraction)
Number of subjects: 21
Study 16896736 — intervention group
Group type: COMPARATOR
Intervention: VR (relaxed muscle)
Number of subjects: 21
Study 16896736 — intervention group
Group type: COMPARATOR
Intervention: NV (no treatment)
Number of subjects: 21
Study 14520020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/day providing 37.0 mg/day lycopene)
Number of subjects: 0
Study 14520020 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot juice (330 ml/day providing 27.1 mg/day beta-carotene and 13.1 mg/day alpha-carotene)
Number of subjects: 0
Study 14520020 — intervention group
Group type: COMPARATOR
Intervention: Depletion period after juice intervention
Number of subjects: 0